Qiagen N.V. (QGEN)
| Market Cap | 10.41B -3.1% |
| Revenue (ttm) | 2.10B +3.0% |
| Net Income | 409.32M +9.6% |
| EPS | 1.97 +10.4% |
| Shares Out | 206.80M |
| PE Ratio | 25.59 |
| Forward PE | 20.18 |
| Dividend | $2.76 (5.48%) |
| Ex-Dividend Date | Jul 7, 2026 |
| Volume | 4,534,884 |
| Open | 50.25 |
| Previous Close | 50.17 |
| Day's Range | 50.15 - 50.38 |
| 52-Week Range | 32.53 - 57.82 |
| Beta | 0.61 |
| Analysts | Hold |
| Price Target | 49.02 (-2.6%) |
| Earnings Date | Nov 4, 2026 |
About QGEN
Qiagen N.V. provides sample to insight solutions that transform biological samples into molecular insights worldwide. The company offers sample technology consumables, such as nucleic acid stabilization and purification kits for sample materials, manual and automated processing for genotyping, gene expression, and viral and bacterial analysis, as well as silica membranes and magnetic bead technologies; secondary sample technology consumables, including kits and components for purification of nucleic acids; and instruments for nucleic acid purif... [Read more]
Financial Performance
In 2025, Qiagen's revenue was $2.09 billion, an increase of 5.65% compared to the previous year's $1.98 billion. Earnings were $424.88 million, an increase of 408.28%.
Financial StatementsAnalyst Summary
According to 12 analysts, the average rating for QGEN stock is "Hold." The 12-month stock price target is $49.02, which is a decrease of -2.60% from the latest price.
News
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Ultralife Corporation (Nasdaq – ULBI), QIAGEN N.V. (NYSE – QGEN), CCC Intelligent Solutions Holdings Inc. (Nasdaq – CCC), Penske Automotive Group, Inc. (NYSE – PAG)
BALA CYNWYD, Pa., Oct. 28, 2026 (GLOBE NEWSWIRE) -- Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky (j...
Qiagen downgraded to Equal Weight from Overweight at Barclays
Barclays downgraded Qiagen (QGEN) to Equal Weight from Overweight with a $53 price target after the company reached an agreement to be acquired by EQT AB for EUR 46.50 per…
Qiagen price target raised to $52 from $45 at Citi
Citi raised the firm’s price target on Qiagen (QGEN) to $52 from $45 and keeps a Neutral rating on the shares after the company agreed to be acquired by EQT…
Qiagen downgraded to Hold from Buy at DZ Bank
DZ Bank analyst Sven Kuerten downgraded Qiagen (QGEN) to Hold from Buy after the company reached an agreement to be acquired by EQT AB for EUR 46.50 per share. Published…
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: QIAGEN N.V. (NYSE – QGEN), Varonis Systems, Inc. (Nasdaq – VRNS), CCC Intelligent Solutions Holdings Inc. (Nasdaq – CCC), Penske Automotive Group, Inc. (NYSE – PAG)
BALA CYNWYD, Pa., Oct. 22, 2026 (GLOBE NEWSWIRE) -- Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky (j...
Qiagen downgraded to Neutral from Outperform at Baird
Baird downgraded Qiagen (QGEN) to Neutral from Outperform with an unchanged price target of $52 after the company reached an agreement to be acquired by EQT AB for EUR 46.50…
Qiagen moved to No Rating at BofA
BofA moved to No Rating on Qiagen (QGEN) after PE firm EQT announced an agreement to acquire the company EUR 46.50 per share in case, equivalent to $52 per share.
Qiagen price target raised to $52 from $50 at Baird
Baird raised the firm’s price target on Qiagen (QGEN) to $52 from $50 and keeps an Outperform rating on the shares. The firm updated its model following its agreement to…
Qiagen downgraded to Neutral from Overweight at JPMorgan
JPMorgan downgraded Qiagen (QGEN) to Neutral from Overweight with a price target of $52, down from $55. The firm cites EQT’s takeover offer of $52.23 per share in cash for…
Qiagen, EQT Private Equity announce $12.1B all-cash takeover offer
Qiagen (QGEN) and the EQT XI fund announced an agreement under which Crown NL Bidco B.V. announced its decision to make an all-cash voluntary public takeover offer for the acquisition…
Qiagen sees Q3 adjusted EPS 65c, consensus 62c
Sees Q3 revenue $548M, consensus $533.91M.
Qiagen suspends 2026 outlook
Qiagen (QGEN) has suspended its full-year 2026 outlook given the announced transaction with EQT Private Equity while the transaction is pending. Qiagen will also not hold a conference call for…
QIAGEN reports preliminary Q3 2026 results
VENLO, Netherlands & GERMANTOWN, Md.--(BUSINESS WIRE)--QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced preliminary third-quarter 2026 financial results. Net sales were $548 mil...
QIAGEN and EQT Private Equity announce agreement on a recommended voluntary all-cash public takeover offer
VENLO, Netherlands & AMSTERDAM--(BUSINESS WIRE)--QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) (“QIAGEN” or the “Company”) and the EQT XI fund (“EQT Private Equity”) today announced an agree...
EQT near acquisition of Qiagen for EUR 46.50 per share, Bloomberg says
EQT AB (EQBBF) (EQBFF) is nearing a deal to acquire Qiagen (QGEN) for around $10.8B or EUR 46.50 per share, above the Wednesday close price of EUR 42.82, Eyk Henning…
EQT near deal to acquire Qiagen for $10.8B, Bloomberg reports
15:38 EDT EQT near deal to acquire Qiagen (QGEN) for $10.8B, Bloomberg reports
Qiagen up 1% to $49.36 after Bloomberg report of possible EQT deal
15:39 EDT Qiagen (QGEN) up 1% to $49.36 after Bloomberg report of possible EQT deal
Qiagen in advanced talks to be acquired by PE firm, Bloomberg says
Swedish buyout firm EQT is in advanced talks to acquire Qiagen (QGEN), people familiar with the matter told Bloomberg’s Eyk Henning and Michelle Davis. Qiagen’s board is meeting this week…
EQT in advanced talks to buy testing firm Qiagen, Bloomberg News reports
European molecular testing company Qiagen is in advanced talks to be acquired by Swedish buyout firm EQT, Bloomberg News reported on Tuesday, citing people familiar with the matter.
Qiagen price target raised to $55 from $50 at JPMorgan
JPMorgan raised the firm’s price target on Qiagen (QGEN) to $55 from $50 and keeps an Overweight rating on the shares. The firm updated models in the life science tools…
QIAGEN Convenes Global Tuberculosis Experts as New Pressures Challenge Progress Against Tuberculosis
VENLO, Netherlands & GERMANTOWN, Md.--(BUSINESS WIRE)---- $QGEN #QIAGEN--QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) will bring together tuberculosis experts from around the world for the ...
Qiagen price target raised to $50 from $49 at BofA
BofA raised the firm’s price target on Qiagen (QGEN) to $50 from $49 and keeps a Buy rating on the shares. The life science tools sector has further re-rated since…
Qiagen announces new AI capabilities for researchers
Qiagen (QGEN) announced new artificial intelligence capabilities to help researchers analyze complex biological and genomic data faster while keeping the scientific evidence behind the results visible...
QIAGEN Expands AI-Powered Bioinformatics for Research and Drug Discovery
VENLO, Netherlands & GERMANTOWN, Md.--(BUSINESS WIRE)---- $QGEN #QIAGEN--QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced new artificial intelligence (AI) capabilities to help r...
Barclays upgrades Qiagen to Overweight ahead of Q3 report
Barclays upgraded Qiagen (QGEN) to Overweight from Equal Weight with a price target of $55, up from $40. The tool sector is positioned for accelerating growth amid “conservative” growth estimates…